Sign up to save your podcasts
Or
Share COPD的用藥新選擇-Ensifentrine 和 Dupilumab
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
COPD的用藥新選擇-Ensifentrine 和 Dupilumab
留言告訴我你對這一集的想法： https://open.firstory.me/user/cl46mafq1001u01zg25tv0l6x/comments
慢性阻塞性肺病（Chronic Obstructive Pulmonary Disease, COPD）是一種由長期呼吸道發炎引起的不可逆呼吸道阻塞疾病。根據 2025 年最新的全球慢性阻塞性肺病倡議臨床指引，治療策略新增了兩種作用機轉不同的新型藥物：Ensifentrine 與 Dupilumab，上述藥物皆於2024年獲得美國食品藥物管理局的許可，相信這兩種新的COPD治療藥物，可以帶給COPD病人更多更好的治療選擇。
文／林柏曄藥師 (社團法人台灣家庭藥師學會)
台灣家庭藥師學會官網: https://familypharm.org/
台灣家庭藥師學會臉書: https://www.facebook.com/profile.php?id=100067147454610
台灣家庭藥師學會IG: https://www.instagram.com/familypharmacist2022/
參考資料：
- 2025 GOLD Report
- Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023;208(4):406-416. doi:10.1164/rccm.202306-0944OC
- Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023;389(3):205-214. doi:10.1056/NEJMoa2303951
- FDA Approves Ensifentrine for Maintenance Treatment of Adult Patients With COPD. https://www.ajmc.com/view/fda-approves-ensifentrine-for-maintenance-treatment-of-adult-patients-with-copd
- FDA Approves Dupilumab as First Biologic Treatment for COPD. https://www.ajmc.com/view/fda-approves-dupilumab-as-first-biologic-treatment-for-copd
圖片來源：https://jamaicahospital.org/clinical-services/pulmonary-medicine/
Powered by Firstory Hosting
View all episodes
By 臺灣家庭藥師學會留言告訴我你對這一集的想法： https://open.firstory.me/user/cl46mafq1001u01zg25tv0l6x/comments
慢性阻塞性肺病（Chronic Obstructive Pulmonary Disease, COPD）是一種由長期呼吸道發炎引起的不可逆呼吸道阻塞疾病。根據 2025 年最新的全球慢性阻塞性肺病倡議臨床指引，治療策略新增了兩種作用機轉不同的新型藥物：Ensifentrine 與 Dupilumab，上述藥物皆於2024年獲得美國食品藥物管理局的許可，相信這兩種新的COPD治療藥物，可以帶給COPD病人更多更好的治療選擇。
文／林柏曄藥師 (社團法人台灣家庭藥師學會)
台灣家庭藥師學會官網: https://familypharm.org/
台灣家庭藥師學會臉書: https://www.facebook.com/profile.php?id=100067147454610
台灣家庭藥師學會IG: https://www.instagram.com/familypharmacist2022/
參考資料：
- 2025 GOLD Report
- Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023;208(4):406-416. doi:10.1164/rccm.202306-0944OC
- Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023;389(3):205-214. doi:10.1056/NEJMoa2303951
- FDA Approves Ensifentrine for Maintenance Treatment of Adult Patients With COPD. https://www.ajmc.com/view/fda-approves-ensifentrine-for-maintenance-treatment-of-adult-patients-with-copd
- FDA Approves Dupilumab as First Biologic Treatment for COPD. https://www.ajmc.com/view/fda-approves-dupilumab-as-first-biologic-treatment-for-copd
圖片來源：https://jamaicahospital.org/clinical-services/pulmonary-medicine/
Powered by Firstory Hosting